Cost comparison of continued anticoagulation with rivaroxaban versus placebo based on the one-year EINSTEIN-Extension trial efficacy and safety results.
CONCLUSIONS: Total healthcare costs were estimated to be lower for patients continuing rivaroxaban therapy compared to those receiving placebo in VTE patients who had completed 6 to 12 months of VTE treatment.
PMID: 29469638 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - Category: Health Management Tags: J Med Econ Source Type: research
More News: Bleeding | Economics | Health Management | Healthcare Costs | Managed Care | Pulmonary Thromboembolism | Study | Thrombosis